|
|
Article: Judge Says Amgen Entitled to Permanent Injunction in EPO Case.
- Article from:
- BIOWORLD Today
- Article date:
- October 6, 2008
- Author:
CopyrightCOPYRIGHT 2008 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Jennifer Boggs, Assistant Managing Editor
A year after a jury ruled that F. Hoffmann-La Roche Ltd.'s PEGylated erythropoietin (EPO) product, Mircera, infringed four of Amgen Inc.'s EPO patents, a District Court judge issued a decision upholding that verdict and said the Thousand Oaks, Calif.-based biotech is entitled to a permanent injunction to block Mircera sales in the U.S. market.
The court previously granted a preliminary injunction to prevent the commercialization of Mircera (methoxy polyethylene glycol-epoetin beta), which gained FDA clearance late last year in anemia associated with chronic kidney disease, and Roche has appealed.
...
Related newspaper, magazine, and journal articles:
|